Skip to main content
SpringerLink
Log in

Sunitinib soars ahead in renal cancer

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Godoy J, Cardona AF, Cáceres H, Otero JM, Lujan M, Lopera D, Pacheco JO, Spath A, Gis P.Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study). 45th Annual Meeting of the American Society of Clinical Oncology: abstr. e16150, 29 May 2009. Available from: URL: http://www.abstract.asco.org

  2. Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S.Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma in the United States. 45th Annual Meeting of the American Society of Clinical Oncology: abstr. e17556, 29 May 2009. Available from: URL: http://www.abstract.asco.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sunitinib soars ahead in renal cancer. Pharmacoecon. Outcomes News 580, 1 (2009). https://doi.org/10.2165/00151234-200905800-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905800-00001

Keywords

Search

Navigation